var data={"title":"Evolocumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Evolocumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/772530?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=evolocumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Evolocumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F36231672\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Repatha;</li>\n      <li>Repatha Pushtronex System;</li>\n      <li>Repatha SureClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45684653\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Repatha</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29871556\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, PCSK9 Inhibitor;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671713\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Homozygous familial hypercholesterolemia (HoFH):</b> SubQ: 420 mg once monthly. <b>Note:</b> Use in combination with diet and other lipid-lowering therapies (eg, statin, ezetimibe, LDL apheresis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing:</i> 420 mg once every 2 weeks (after 12 weeks, may decrease to 420 mg once a month) in conjunction with lipid apheresis has been studied in a limited number of patients (Bruckert 2014). The European Atherosclerosis Society recommends administration directly after lipid apheresis (EAS [France 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperlipidemia, primary (including heterozygous familial hyperlipidemia [HeFH]):</b> SubQ: 140 mg every 2 weeks or 420 mg once monthly. <b>Note:</b> Use in combination with diet and an optimized regimen of lipid-lowering therapy (eg, maximum tolerated dose of statin) (Sabatine 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching regimens:</i> Administer the first dose of the new regimen on the next scheduled day of the prior regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiovascular events in patients with established CVD:</b> SubQ: 140 mg every 2 weeks or 420 mg once monthly. <b>Note:</b> Use in combination with an optimized regimen of lipid-lowering therapy (eg, high-intensity statin) (Sabatine 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching regimens:</i> Administer the first dose of the new regimen on the next scheduled day of the prior regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed dose:</i> Administer within 7 days from the missed dose and resume original schedule. If an every-2-week dose is not administered within 7 days, wait until the next dose on the original schedule. If a once-monthly dose is not administered within 7 days, administer the dose and start a new schedule based on this date.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671701\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Homozygous familial hypercholesterolemia:</b> Adolescents 13 to 17 years: SubQ: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed dose:</i> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671716\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671719\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671722\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child Pugh classes A and B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F36231673\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Repatha SureClick: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Repatha Pushtronex System: 420 mg/3.5 mL (3.5 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Repatha: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F36231671\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671726\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For SubQ administration. Do not shake. If refrigerated, allow to stand at room temperature for at least 30 minutes (single-use prefilled autoinjector or single-use prefilled syringe) or at least 45 minutes (single-use on-body infusor with prefilled cartridge) prior to use (do not warm with heat or hot water). Administer into areas of the abdomen (except for the 2-inch area around the navel), thigh, or upper arm; only use areas that are not tender, bruised, red, or indurated. Do not coadminister with other injectable drugs at the same injection site. Rotate the injection site with each injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Once-monthly dose (ie, 420 mg): Administer SubQ over 9 minutes using the single-use infusor with prefilled cartridge <b>or</b> give 3 separate SubQ 140 mg injections consecutively within a 30-minute period using the single-use prefilled autoinjector or single-use prefilled syringe.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29871557\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Homozygous familial hypercholesterolemia:</b> Adjunct to diet and other LDL-lowering therapies (eg, statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperlipidemia, primary <b>(including heterozygous familial hyperlipidemia)</b>: </b>Adjunct to diet, alone or in combination with other lipid-lowering therapies (eg, maximum tolerated dose of statins), for the treatment of adults with primary hyperlipidemia, including heterozygous familial hyperlipidemia (HeFH), to reduce LDL-C (Sabatine 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cardiovascular events in patients with established cardiovascular disease:</b> To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD). <b>Note:</b> Use in combination with an optimized regimen of lipid-lowering therapy (eg, high-intensity statin) (Sabatine 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45748325\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Evolocumab may be confused with elotuzumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F43721667\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">&gt;10%: Respiratory: Nasopharyngitis (6% to 11%)</p>\n    <p style=\"text-indent:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4%), fatigue (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroenteritis (3% to 6%), nausea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; Oncologic: Bruise (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (8% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (including erythema, pain, bruising: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; Skeletal: Myalgia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (9%), cough (1% to 5%), sinusitis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Antibody development, decreased LDL cholesterol (&lt;25 mg/dL), hypersensitivity, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29871558\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity to evolocumab or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for PCSK9 inhibitors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671628\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria) have been reported, some requiring discontinuation. Discontinue treatment and initiate supportive treatment in patients who develop signs/symptoms of serious allergic reaction; monitor until symptoms resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: The packaging (needle cap of prefilled syringe and autoinjector) may contain dry natural rubber, which is a derivative of latex.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44576019\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671632\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=103780&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671620\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. IgG antibodies are known to cross the placenta in increasing amounts during the second and third trimesters; exposure of the fetus to evolocumab is expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671623\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if evolocumab is present in breast milk. However, IgG antibodies are present in human milk; available data suggest that concentrations do not reach the neonatal circulation in substantial amounts. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671734\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Lipid profile; in patients with homozygous familial hypercholesterolemia, measure LDL-C levels 4 to 8 weeks after initiation (response to evolocumab will depend on degree of LDL-receptor function); signs/symptoms of hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51237666\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations (NLA [Jacobson 2015]):</b> Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk </i>category), treating to a non-HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671644\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9).  PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL; therefore, the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-cholesterol (LDL-C). By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F34671657\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Peak effect: Proprotein convertase subtilisin kexin type 9 (PCSK9) suppression: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: IV: V<sub>d</sub>: ~3.3 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nonsaturable proteolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 72%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 11 to 17 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: SubQ: 3 to 4 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45088623\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Repatha SureClick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/mL (1 mL): $670.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Repatha Pushtronex System Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420MG/3.5ML (3.5 mL): $1,452.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Repatha Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/mL (1 mL): $670.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45784050\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Repatha (AT, BB, CR, CZ, DK, DO, EE, ES, GB, GT, HK, HN, HR, HU, IE, LT, NI, NL, NO, PA, PL, PT, SE, SG, SK, SV);</li>\n      <li>Repatha-SC (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Blom DJ, Hala T, Bolognese M, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. <i>N Engl J Med</i>. 2014;370(19):1809-1819.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/24678979/pubmed\" target=\"_blank\" id=\"24678979\">24678979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruckert E, Blaha V, Stein EA, et al. Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis. Circulation. 2014;130(s2):17016 [Abstract from 2014 AHA/ASA meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27839699\"></a>France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. <i>Atherosclerosis</i>. 2016;255:128-139. doi: 10.1016/j.atherosclerosis.2016.10.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/27839699/pubmed\" target=\"_blank\" id=\"27839699\">27839699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/25911072/pubmed\" target=\"_blank\" id=\"25911072\">25911072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Repatha (evolocumab) [prescribing information]. Thousand Oaks, CA: Amgen; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raal FJ, Honarpour N, Blom DJ, et al; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015;385(9965):341-350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/25282520/pubmed\" target=\"_blank\" id=\"25282520\">25282520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raal FJ, Stein EA, Dufour R, et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015;385(9965):331-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/25282519/pubmed\" target=\"_blank\" id=\"25282519\">25282519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson JG, Nedergaard BS, Rogers WJ, et al; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <i>JAMA</i>. 2014;311(18):1870-1882.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/24825642/pubmed\" target=\"_blank\" id=\"24825642\">24825642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28304224\"></a>Sabatine MS, Giugliano RP, Keech AC, et al: FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med</i>. 2017;376(18):1713-1722. doi: 10.1056/NEJMoa1615664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/28304224/pubmed\" target=\"_blank\" id=\"28304224\">28304224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25773607\"></a>Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>N Engl J Med</i>. 2015;372(16):1500-1509.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/evolocumab-drug-information/abstract-text/25773607/pubmed\" target=\"_blank\" id=\"25773607\">25773607</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 103780 Version 50.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F36231672\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45684653\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F29871556\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F34671713\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F34671701\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F34671716\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F34671719\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F34671722\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F36231673\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F36231671\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F34671726\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F29871557\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45748325\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F43721667\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F29871558\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F34671628\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F44576019\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F34671632\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F34671620\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F34671623\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F34671734\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F51237666\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F34671644\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F34671657\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45088623\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45784050\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/103780|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=evolocumab-patient-drug-information\" class=\"drug drug_patient\">Evolocumab: Patient drug information</a></li></ul></div></div>","javascript":null}